贝达喹啉联合莫西沙星治疗耐多药肺结核的临床效果  

Clinical efficacy of bedaquiline combined with moxifloxacin in the treatment of multidrug-resistant pulmonary tuberculosis

作　　者：廉桃梅 李坤营 梁维娟[3] 贾会英 白玺 崔晓华[6] 杨莉 陈瑛[7] LIAN Taomei;LI Kunying;LIANG Weijuan;JIA Huiying;BAI Xi;CUI Xiaohua;YANG Li;CHEN Ying(Department of Tuberculosis,Henan Chest Hospital,Zhengzhou Henan 450000,China;Department of the Endoscopy Center,Henan Chest Hospital,Zhengzhou Henan 450000,China;Department of Infection,Jiyuan People's Hospital,Jiyuan Henan 459000,China;Department of the First Tuberculosis,The Fifth People's Hospital of Puyang of Henan Province,Puyang Henan 457000,China;Department of the First Tuberculosis Ward,Henan Chest Hospital,Zhengzhou Henan 450000,China;Department of First Ward of Tuberculosis,Henan Chest Hospital,Zhengzhou Henan 450000,China)

机构地区：[1]河南省胸科医院结核科,河南郑州450000 [2]河南省胸科医院内镜中心,河南郑州450000 [3]济源市人民医院感染科,河南济源459000 [4]河南省濮阳市第五人民医院结核一科,河南濮阳457000 [5]河南省胸科医院结核一病区,河南郑州450000 [6]河南省胸科医院结核内科,河南郑州450000 [7]河南省胸科医院结核内科一病区,河南郑州450000

出　　处：《临床研究》2023年第5期69-72,共4页Clinical Research

基　　金：应用新型球囊导管行支气管肺泡灌洗术预防感染播散的有效性评估(SB201902035)。

摘　　要：目的探讨耐多药肺结核(MDR-TB)患者采用贝达喹啉联合莫西沙星治疗的临床效果。方法选取河南省胸科医院2020年2月至2022年10月收治的MDR-TB患者共计116例,以随机数字表法分为研究组(N=58,贝达喹啉联合莫西沙星治疗)与对照组(N=58,莫西沙星治疗),对两组临床疗效、临床症状、免疫功能、生活质量及不良反应进行比较。结果研究组治疗有效率(94.83%)高于对照组(81.03%),差异有统计学意义(P<0.05);治疗后两组咳嗽、胸闷、气喘、咳血症状评分降低,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后两组免疫球蛋白(Ig)A、IgM、IgG水平提高,且研究组高于对照组,差异有统计学意义(P<0.05);治疗后两组世界卫生组织生存质量测定量表简表(WHOQOL-BREF)评分提高,且研究组高于对照组,差异有统计学意义(P<0.05);研究组不良反应发生率(17.24%)与对照组(10.34%)比较,差异无统计学意义(P>0.05)。结论MDR-TB患者给予贝达喹啉联合莫西沙星治疗能够提升临床疗效,改善症状,提高免疫功能,改善生活质量,不会增加不良反应。Objective To investigate the clinical effect of bedaquiline combined with moxifloxacin in the treatment of multidrug resistant tuberculosis(MDR-TB).Methods A total of 116 MDR-TB patients admitted to Henan Chest Hospital from February 2020 to October 2022 were selected and divided into a study group(N=58,Bedaquinoline combined with moxifloxacin)and control group(N=58,moxifloxacin)by random number table method.The clinical efficacy,clinical symptoms,immune function,quality of life,and adverse reactions of the two groups were compared.Results The effective rate of the study group(94.83%)was higher than that of the control group(81.03%),and the difference was statistically significant(P<0.05).After treatment,symptom scores of cough,chest tightness,asthma,and hemoptysis were decreased in the two groups,and the study group was lower than the control group,the difference was statistically significant(P<0.05).After treatment,the levels of immunoglobulin(Ig)A,IgM,and IgG in the two groups were increased,and the research group was higher than the control group,the difference was statistically significant(P<0.05).After treatment,the world health organization quality of Life scale scores(WHOQOL-BREF)of the two groups increased,and the scores of the study group were higher than those of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the study group(17.24%)and the control group(10.34%)(P>0.05).Conclusion MDR-TB patients treated with Bedaquinoline combined with moxifloxacin can improve clinical efficacy,improve symptoms,improve immune function,and improve quality of life without increasing adverse reactions.

关 键 词：贝达喹啉 莫西沙星 耐多药肺结核 临床效果 

分 类 号：R521[医药卫生—内科学]